RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
China Medical System (CMS) of Shenzhen in-licensed greater China rights for two prescription drugs from India’s Sun Pharma, a treatment for dry eye and a biologic treatment for psoriasis. The two patented drugs will be the first Sun Pharma products available in China. CMS will make an upfront payment to Sun Pharma, plus pay regulatory/sales milestones and royalties on sales. Further details are confidential. CMS, which will be responsible for China regulatory approvals of the products, will have rights to the products for 15 years.
Source: China Biotoday
